GE HealthCare said 2024 total revenues were $19,672 million, growing 1% or $120 million, and China region revenues were $2,360 million, declining 15%. The company cited the delay in the 2024 stimulus and the ongoing anti-corruption campaign as factors that contributed to delayed orders and sales in China.

1. 01

   GE HealthCare said 2024 total revenues were $19,672 million, growing 1% or $120 million, and China region revenues were $2,360 million, declining 15%. The company cited the delay in the 2024 stimulus and the ongoing anti-corruption campaign as factors that contributed to delayed orders and sales in China.

2. 02

   GE HealthCare said 2024 operating income was $2,625 million, an increase of $190 million, and net income attributable to GE HealthCare was $1,993 million with a net income margin of 10.1%, while Adjusted EBIT was $3,211 million with an Adjusted EBIT margin of 16.3%.

3. 03

   GE HealthCare said 2024 cash from operating activities was $1,955 million and cash used for investing activities was $914 million. Investing activities included additions of PP&E of $401 million and net cash used for acquisitions of $313 million after deducting cash acquired in connection with the acquisitions of MIM Software and Intelligent Ultrasound Group PLC.

4. 04

   GE HealthCare said 2024 cash used for financing activities was $573 million. This included repayment of senior unsecured notes of $1,000 million and repayment of the Term Loan Facility of $400 million, partially offset by net proceeds from the issuance of 2029 maturity notes of $1,000 million and $995 million.

Key figures

Fiscal year ended December 31, 2024

Revenue

$19.7B

Operating income

$2.6B

Net income

$2.0B

EPS

$4.34

Gross profit

$8.2B

Operating cash flow

$2.0B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.